Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Review

The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer

Authors: Joseph R. Inigo, Dhyan Chandra

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

Mitochondria are essential for tumor growth and progression. However, the heavy demand for mitochondrial activity in cancer leads to increased production of mitochondrial reactive oxygen species (mtROS), accumulation of mutations in mitochondrial DNA, and development of mitochondrial dysfunction. If left unchecked, excessive mtROS can damage and unfold proteins in the mitochondria to an extent that becomes lethal to the tumor. Cellular systems have evolved to combat mtROS and alleviate mitochondrial stress through a quality control mechanism called the mitochondrial unfolded protein response (UPRmt). The UPRmt system is composed of chaperones and proteases, which promote protein folding or eliminate mitochondrial proteins damaged by mtROS, respectively. UPRmt is conserved and activated in cancer in response to mitochondrial stress to maintain mitochondrial integrity and support tumor growth. In this review, we discuss how mitochondria become dysfunctional in cancer and highlight the tumor-promoting functions of key components of the UPRmt.
Literature
1.
Hartwell LH, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278(5340):1064–8.PubMedCrossRef
2.
3.
4.
5.
6.
7.
8.
9.
Galadari S, et al. Reactive oxygen species and cancer paradox: to promote or to suppress? Free Radic Biol Med. 2017;104:144–64.PubMedCrossRef
10.
11.
Martinus RD, et al. Selective induction of mitochondrial chaperones in response to loss of the mitochondrial genome. Eur J Biochem. 1996;240(1):98–103.PubMedCrossRef
12.
13.
14.
15.
Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21(24):3214–31.PubMedCrossRef
16.
Fisher GH, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001;15(24):3249–62.PubMedPubMedCentralCrossRef
17.
Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4(2):199–207.PubMedCrossRef
18.
Velu TJ, et al. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science. 1987;238(4832):1408–10.PubMedCrossRef
19.
Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science. 2002;297(5578):63–4.PubMedCrossRef
20.
Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med. 2011;3(11):623–36.PubMedPubMedCentralCrossRef
21.
Solimini NL, et al. Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007;130(6):986–8.PubMedCrossRef
22.
23.
Haas RH. Mitochondrial dysfunction in aging and diseases of aging. Biology (Basel). 2019;8(2):48.
24.
Kenny TC, et al. The mitochondrial unfolded protein response as a non-oncogene addiction to support adaptation to stress during transformation in cancer and beyond. Front Oncol. 2017;7:159.PubMedPubMedCentralCrossRef
25.
26.
Taanman JW. The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta. 1999;1410(2):103–23.PubMedCrossRef
27.
28.
Meyer JN, et al. Mitochondrial fusion, fission, and mitochondrial toxicity. Toxicology. 2017;391:42–53.PubMedCrossRef
29.
30.
Chandel NS. Metabolism of proliferating cells. Cold Spring Harb Perspect Biol. 2021;13(10):a040618.PubMedCrossRef
31.
Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMedCrossRef
32.
33.
Huttemann M, et al. Regulation of mitochondrial oxidative phosphorylation through cell signaling. Biochim Biophys Acta. 2007;1773(12):1701–20.PubMedCrossRef
34.
Quinlan CL, et al. The 2-oxoacid dehydrogenase complexes in mitochondria can produce superoxide/hydrogen peroxide at much higher rates than complex I. J Biol Chem. 2014;289(12):8312–25.PubMedPubMedCentralCrossRef
35.
Brand MD. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radic Biol Med. 2016;100:14–31.PubMedCrossRef
36.
Evans MD, et al. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res. 2004;567(1):1–61.PubMedCrossRef
37.
Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc. 2010;5(1):51–66.PubMedCrossRef
38.
Wei YH, et al. Mitochondrial theory of aging matures–roles of mtDNA mutation and oxidative stress in human aging. Zhonghua Yi Xue Za Zhi (Taipei). 2001;64(5):259–70.
39.
40.
Larsen NB, et al. Nuclear and mitochondrial DNA repair: similar pathways? Mitochondrion. 2005;5(2):89–108.PubMedCrossRef
41.
42.
Nicolson GL. Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Integr Med (Encinitas). 2014;13(4):35–43.
43.
44.
45.
Shidara Y, et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res. 2005;65(5):1655–63.PubMedCrossRef
46.
47.
Polyak K, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998;20(3):291–3.PubMedCrossRef
48.
Park JS, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet. 2009;18(9):1578–89.PubMedPubMedCentralCrossRef
49.
Liou GY, et al. Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions. Cell Rep. 2016;14(10):2325–36.PubMedPubMedCentralCrossRef
50.
Kwon J, et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A. 2004;101(47):16419–24.PubMedPubMedCentralCrossRef
51.
Garcia-Santamarina S, et al. Reversible cysteine oxidation in hydrogen peroxide sensing and signal transduction. Biochemistry. 2014;53(16):2560–80.PubMedCrossRef
52.
53.
54.
Zhou C, et al. Redox regulation by SOD2 modulates colorectal cancer tumorigenesis through AMPK-mediated energy metabolism. Mol Carcinog. 2020;59(5):545–56.PubMedCrossRef
55.
Lim JM, et al. Control of the pericentrosomal H2O2 level by peroxiredoxin I is critical for mitotic progression. J Cell Biol. 2015;210(1):23–33.PubMedCrossRef
56.
Weinberg F, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107(19):8788–93.PubMedPubMedCentralCrossRef
57.
Qi L, et al. HMGB1 promotes mitochondrial dysfunction-triggered striatal neurodegeneration via autophagy and apoptosis activation. PLoS ONE. 2015;10(11): e0142901.PubMedPubMedCentralCrossRef
58.
59.
Kang R, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene. 2014;33(5):567–77.PubMedCrossRef
60.
Chen Q, et al. Rewiring of glutamine metabolism is a bioenergetic adaptation of human cells with mitochondrial DNA mutations. Cell Metab. 2018;27(5):1007-1025 e5.PubMedPubMedCentralCrossRef
61.
Khasawneh J, et al. Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A. 2009;106(9):3354–9.PubMedPubMedCentralCrossRef
62.
Wang C, et al. Elevated level of mitochondrial reactive oxygen species via fatty acid beta-oxidation in cancer stem cells promotes cancer metastasis by inducing epithelial-mesenchymal transition. Stem Cell Res Ther. 2019;10(1):175.PubMedPubMedCentralCrossRef
63.
64.
65.
Frenkel K. Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol Ther. 1992;53(1):127–66.PubMedCrossRef
66.
Shacter E, et al. Activated neutrophils induce prolonged DNA damage in neighboring cells. Carcinogenesis. 1988;9(12):2297–304.PubMedCrossRef
67.
Wang J, et al. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019;8(10):4709–21.PubMedPubMedCentralCrossRef
68.
Trush MA, Kensler TW. An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Radic Biol Med. 1991;10(3–4):201–9.PubMedCrossRef
69.
Hahn WS, et al. Proinflammatory cytokines differentially regulate adipocyte mitochondrial metabolism, oxidative stress, and dynamics. Am J Physiol Endocrinol Metab. 2014;306(9):E1033–45.PubMedPubMedCentralCrossRef
70.
Lopez-Armada MJ, et al. Mitochondrial activity is modulated by TNFalpha and IL-1beta in normal human chondrocyte cells. Osteoarthritis Cartilage. 2006;14(10):1011–22.PubMedCrossRef
71.
El Jamal SM, et al. Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways. Cell Div. 2016;11:11.PubMedPubMedCentralCrossRef
72.
Cao Y, et al. Proinflammatory cytokines stimulate mitochondrial superoxide flashes in articular chondrocytes in vitro and in situ. PLoS ONE. 2013;8(6): e66444.PubMedPubMedCentralCrossRef
73.
Yang D, et al. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res. 2007;85(4):462–72.PubMedPubMedCentralCrossRef
74.
Muz B, et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83–92.CrossRef
75.
Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625–34.PubMedCrossRef
76.
Huang LE, et al. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998;95(14):7987–92.PubMedPubMedCentralCrossRef
77.
78.
Chandel NS, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000;275(33):25130–8.PubMedCrossRef
79.
Bell EL, et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol. 2007;177(6):1029–36.PubMedPubMedCentralCrossRef
80.
81.
Mizutani S, et al. Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs. Cancer Sci. 2009;100(9):1680–7.PubMedCrossRef
82.
Guerra F, et al. Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance. J Clin Oncol. 2012;30(36):e373–8.PubMedCrossRef
83.
Okon IS, et al. Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells. J Biol Chem. 2015;290(14):9101–10.PubMedPubMedCentralCrossRef
84.
85.
Kulawiec M, et al. mtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice. J Hum Genet. 2009;54(11):647–54.PubMedPubMedCentralCrossRef
86.
87.
88.
89.
Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904.PubMedCrossRef
90.
91.
Sun HF, et al. Loss of TMEM126A promotes extracellular matrix remodeling, epithelial-to-mesenchymal transition, and breast cancer metastasis by regulating mitochondrial retrograde signaling. Cancer Lett. 2019;440–441:189–201.PubMedCrossRef
92.
Dasgupta S, et al. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol. 2012;227(6):2451–60.PubMedPubMedCentralCrossRef
93.
Ishikawa K, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320(5876):661–4.PubMedCrossRef
94.
Yuan Y, et al. Nonsense and missense mutation of mitochondrial ND6 gene promotes cell migration and invasion in human lung adenocarcinoma. BMC Cancer. 2015;15:346.PubMedPubMedCentralCrossRef
95.
Koshikawa N, et al. Association of predicted pathogenic mutations in mitochondrial ND genes with distant metastasis in NSCLC and colon cancer. Sci Rep. 2017;7(1):15535.PubMedPubMedCentralCrossRef
96.
97.
98.
Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol. 1997;12(2):525–35.PubMed
99.
Cobanoglu U, et al. Erythrocyte catalase and carbonic anhydrase activities in lung cancer. Asian Pac J Cancer Prev. 2010;11(5):1377–82.PubMed
100.
Oltra AM, et al. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med. 2001;30(11):1286–92.PubMedCrossRef
101.
Balasubramaniyan N, et al. Status of antioxidant systems in human carcinoma of uterine cervix. Cancer Lett. 1994;87(2):187–92.PubMedCrossRef
102.
Nishida S, et al. Manganese superoxide dismutase content and localization in human thyroid tumours. J Pathol. 1993;169(3):341–5.PubMedCrossRef
103.
Peddireddy V, et al. Assessment of 8-oxo-7, 8-dihydro-2’-deoxyguanosine and malondialdehyde levels as oxidative stress markers and antioxidant status in non-small cell lung cancer. Biomarkers. 2012;17(3):261–8.PubMedCrossRef
104.
105.
Genova ML, Lenaz G. The interplay between respiratory supercomplexes and ROS in aging. Antioxid Redox Signal. 2015;23(3):208–38.PubMedCrossRef
106.
107.
Harbauer AB, et al. The protein import machinery of mitochondria-a regulatory hub in metabolism, stress, and disease. Cell Metab. 2014;19(3):357–72.PubMedCrossRef
108.
Schmidt O, et al. Mitochondrial protein import: from proteomics to functional mechanisms. Nat Rev Mol Cell Biol. 2010;11(9):655–67.PubMedCrossRef
109.
110.
111.
Yoneda T, et al. Compartment-specific perturbation of protein handling activates genes encoding mitochondrial chaperones. J Cell Sci. 2004;117(Pt 18):4055–66.PubMedCrossRef
112.
Haynes CM, et al. ClpP mediates activation of a mitochondrial unfolded protein response in C. elegans. Dev Cell. 2007;13(4):467–80.PubMedCrossRef
113.
114.
Nargund AM, et al. Mitochondrial and nuclear accumulation of the transcription factor ATFS-1 promotes OXPHOS recovery during the UPR(mt). Mol Cell. 2015;58(1):123–33.PubMedPubMedCentralCrossRef
115.
116.
Schulz AM, Haynes CM. (2015) UPR(mt)-mediated cytoprotection and organismal aging. Biochim Biophys Acta. 1847;11:1448–56.
117.
Nishitoh H. CHOP is a multifunctional transcription factor in the ER stress response. J Biochem. 2012;151(3):217–9.PubMedCrossRef
118.
Harding HP, et al. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell. 2000;5(5):897–904.PubMedCrossRef
119.
120.
121.
Mohrin M, et al. Stem cell aging. A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. Science. 2015;347(6228):1374–7.PubMedPubMedCentralCrossRef
122.
Katiyar A, et al. HSF1 is required for induction of mitochondrial chaperones during the mitochondrial unfolded protein response. FEBS Open Bio. 2020;10(6):1135–48.PubMedPubMedCentralCrossRef
123.
Horibe T, Hoogenraad NJ. The chop gene contains an element for the positive regulation of the mitochondrial unfolded protein response. PLoS ONE. 2007;2(9): e835.PubMedPubMedCentralCrossRef
124.
Pirkkala L, et al. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 2001;15(7):1118–31.PubMedCrossRef
125.
Zhang HH, et al. Sirtuin-3 (SIRT3) protects pancreatic beta-cells from endoplasmic reticulum (ER) stress-induced apoptosis and dysfunction. Mol Cell Biochem. 2016;420(1–2):95–106.PubMedCrossRef
126.
127.
Livezey M, et al. A new role for estrogen receptor alpha in cell proliferation and cancer: activating the anticipatory unfolded protein response. Front Endocrinol (Lausanne). 2018;9:325.CrossRef
128.
Zhou Z, et al. Estrogen receptor alpha protects pancreatic beta-cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress. J Biol Chem. 2018;293(13):4735–51.PubMedPubMedCentralCrossRef
129.
Chiribau CB, et al. Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis. Mol Cell Biol. 2010;30(14):3722–31.PubMedPubMedCentralCrossRef
130.
Teske BF, et al. CHOP induces activating transcription factor 5 (ATF5) to trigger apoptosis in response to perturbations in protein homeostasis. Mol Biol Cell. 2013;24(15):2477–90.PubMedPubMedCentralCrossRef
131.
Zhou D, et al. Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions. J Biol Chem. 2008;283(11):7064–73.PubMedCrossRef
132.
Torres-Peraza JF, et al. Protective neuronal induction of ATF5 in endoplasmic reticulum stress induced by status epilepticus. Brain. 2013;136(Pt 4):1161–76.PubMedCrossRef
133.
134.
Tyynismaa H, et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet. 2010;19(20):3948–58.PubMedCrossRef
135.
Dogan SA, et al. Tissue-specific loss of DARS2 activates stress responses independently of respiratory chain deficiency in the heart. Cell Metab. 2014;19(3):458–69.PubMedCrossRef
136.
137.
Smyrnias I, et al. Cardioprotective effect of the mitochondrial unfolded protein response during chronic pressure overload. J Am Coll Cardiol. 2019;73(14):1795–806.PubMedPubMedCentralCrossRef
138.
Beissinger M, Buchner J. How chaperones fold proteins. Biol Chem. 1998;379(3):245–59.PubMed
139.
140.
Gottesman S, et al. The ClpXP and ClpAP proteases degrade proteins with carboxy-terminal peptide tails added by the SsrA-tagging system. Genes Dev. 1998;12(9):1338–47.PubMedPubMedCentralCrossRef
141.
Young L, et al. Role of the ABC transporter Mdl1 in peptide export from mitochondria. Science. 2001;291(5511):2135–8.PubMedCrossRef
142.
Bezawork-Geleta A, et al. LON is the master protease that protects against protein aggregation in human mitochondria through direct degradation of misfolded proteins. Sci Rep. 2015;5:17397.PubMedPubMedCentralCrossRef
143.
144.
Baxevanis AD, Vinson CR. Interactions of coiled coils in transcription factors: where is the specificity? Curr Opin Genet Dev. 1993;3(2):278–85.PubMedCrossRef
145.
Ellenberger TE, et al. The GCN4 basic region leucine zipper binds DNA as a dimer of uninterrupted alpha helices: crystal structure of the protein-DNA complex. Cell. 1992;71(7):1223–37.PubMedCrossRef
146.
147.
Angelastro JM, et al. Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. J Neurosci. 2003;23(11):4590–600.PubMedPubMedCentralCrossRef
148.
Sun X, et al. Dominant-negative ATF5 compromises cancer cell survival by targeting CEBPB and CEBPD. Mol Cancer Res. 2020;18(2):216–28.PubMedCrossRef
149.
Feldheim J, et al. Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients. Onco Targets Ther. 2018;11:8673–84.PubMedPubMedCentralCrossRef
150.
Monaco SE, et al. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer. 2007;120(9):1883–90.PubMedCrossRef
151.
Hu M, et al. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis. Anticancer Res. 2012;32(10):4385–94.PubMed
152.
153.
Chen A, et al. ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells. Int J Gynecol Pathol. 2012;31(6):532–7.PubMedCrossRef
154.
Sheng Z, et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med. 2010;16(6):671–7.PubMedPubMedCentralCrossRef
155.
156.
Wang H, et al. ATF5 promotes cell survival through transcriptional activation of Hsp27 in H9c2 cells. Cell Biol Int. 2007;31(11):1309–15.PubMedCrossRef
157.
Watatani Y, et al. Amino acid limitation induces expression of ATF5 mRNA at the post-transcriptional level. Life Sci. 2007;80(9):879–85.PubMedCrossRef
158.
Pei Z, et al. Transcriptomic and functional pathways analysis of ascorbate-induced cytotoxicity and resistance of Burkitt lymphoma. Oncotarget. 2016;7(39):63950–9.PubMedPubMedCentralCrossRef
159.
Liu DX, et al. p300-Dependent ATF5 acetylation is essential for Egr-1 gene activation and cell proliferation and survival. Mol Cell Biol. 2011;31(18):3906–16.PubMedPubMedCentralCrossRef
160.
Dluzen D, et al. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner. J Biol Chem. 2011;286(9):7705–13.PubMedPubMedCentralCrossRef
161.
Karpel-Massler G, et al. A synthetic cell-penetrating dominant-negative ATF5 peptide exerts anticancer activity against a broad spectrum of treatment-resistant cancers. Clin Cancer Res. 2016;22(18):4698–711.PubMedPubMedCentralCrossRef
162.
Levy-Rimler G, et al. The effect of nucleotides and mitochondrial chaperonin 10 on the structure and chaperone activity of mitochondrial chaperonin 60. Eur J Biochem. 2001;268(12):3465–72.PubMedCrossRef
163.
Okamoto T, et al. Functional structure and physiological functions of mammalian wild-type HSP60. Arch Biochem Biophys. 2015;586:10–9.PubMedCrossRef
164.
Gomez-Llorente, Y. et al. (2020) Structural basis for active single and double ring complexes in human mitochondrial Hsp60-Hsp10 chaperonin. Nat Commun 11 (1), 1916.
165.
166.
Sarangi U, et al. Hsp60 chaperonin acts as barrier to pharmacologically induced oxidative stress mediated apoptosis in tumor cells with differential stress response. Drug Target Insights. 2013;7:35–51.PubMedPubMedCentralCrossRef
167.
Marino Gammazza A, et al. Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence. Cancer Lett. 2017;385:75–86.PubMedCrossRef
168.
Cappello F, et al. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res. 2003;23(2B):1325–31.PubMed
169.
Rappa F, et al. Quantitative patterns of Hsps in tubular adenoma compared with normal and tumor tissues reveal the value of Hsp10 and Hsp60 in early diagnosis of large bowel cancer. Cell Stress Chaperones. 2016;21(5):927–33.PubMedPubMedCentralCrossRef
170.
Lim SO, et al. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol. 2005;11(14):2072–9.PubMedPubMedCentralCrossRef
171.
Mano R, et al. Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guerin immunotherapy. Urol Oncol. 2018;36(12):531 e9-531 e17.CrossRef
172.
Castilla C, et al. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer. Urology. 2010;76(4):1017 e1-1026.CrossRef
173.
Zhou C, et al. Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth. Cell Death Dis. 2018;9(2):161.PubMedPubMedCentralCrossRef
174.
175.
Vocka M, et al. Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer. Oncol Lett. 2019;18(6):6284–92.PubMedPubMedCentral
176.
177.
Kim W, et al. CCAR2/DBC1 and Hsp60 Positively Regulate Expression of Survivin in Neuroblastoma Cells. Int J Mol Sci. 2019;20(1):131.PubMedCentralCrossRef
178.
179.
180.
181.
182.
183.
Tsai YP, et al. Interaction between HSP60 and beta-catenin promotes metastasis. Carcinogenesis. 2009;30(6):1049–57.PubMedCrossRef
184.
Tsai YP, et al. Direct regulation of HSP60 expression by c-MYC induces transformation. FEBS Lett. 2008;582(29):4083–8.PubMedCrossRef
185.
Chaiwatanasirikul KA, Sala A. The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death Dis. 2011;2: e219.PubMedPubMedCentralCrossRef
186.
Kim W, et al. Mitochondrial CCAR2/DBC1 is required for cell survival against rotenone-induced mitochondrial stress. Biochem Biophys Res Commun. 2017;485(4):782–9.PubMedCrossRef
187.
Lin CY, et al. Oxidation of heat shock protein 60 and protein disulfide isomerase activates ERK and migration of human hepatocellular carcinoma HepG2. Oncotarget. 2016;7(10):11067–82.PubMedPubMedCentralCrossRef
188.
Chandra D, et al. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J Biol Chem. 2007;282(43):31289–301.PubMedCrossRef
189.
Campanella C, et al. The odyssey of Hsp60 from tumor cells to other destinations includes plasma membrane-associated stages and Golgi and exosomal protein-trafficking modalities. PLoS ONE. 2012;7(7): e42008.PubMedPubMedCentralCrossRef
190.
Campanella C, et al. Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery. Cancer. 2015;121(18):3230–9.PubMedCrossRef
191.
Samali A, et al. Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J. 1999;18(8):2040–8.PubMedPubMedCentralCrossRef
192.
193.
Kirchhoff SR, et al. Cytosolic heat shock protein 60, apoptosis, and myocardial injury. Circulation. 2002;105(24):2899–904.PubMedCrossRef
194.
Chang AY, et al. Heat shock protein 60 in rostral ventrolateral medulla reduces cardiovascular fatality during endotoxaemia in the rat. J Physiol. 2006;574(Pt 2):547–64.PubMedPubMedCentralCrossRef
195.
196.
Shin BK, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem. 2003;278(9):7607–16.PubMedCrossRef
197.
Feng H, et al. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood. 2002;100(12):4108–15.PubMedCrossRef
198.
Piselli P, et al. Different expression of CD44, ICAM-1, and HSP60 on primary tumor and metastases of a human pancreatic carcinoma growing in scid mice. Anticancer Res. 2000;20(2A):825–31.PubMed
199.
Barazi HO, et al. Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res. 2002;62(5):1541–8.PubMed
200.
Tawil NJ, et al. Integrin alpha3beta1 can promote adhesion and spreading of metastatic breast carcinoma cells on the lymph node stroma. Int J Cancer. 1996;66(5):703–10.PubMedCrossRef
201.
Lundstrom A, et al. The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun. 1998;250(3):735–40.PubMedCrossRef
202.
Lemmon SK, Traub LM. Sorting in the endosomal system in yeast and animal cells. Curr Opin Cell Biol. 2000;12(4):457–66.PubMedCrossRef
203.
204.
Hayoun D, et al. HSP60 is transported through the secretory pathway of 3-MCA-induced fibrosarcoma tumour cells and undergoes N-glycosylation. FEBS J. 2012;279(12):2083–95.PubMedCrossRef
205.
Cappello F, et al. Immunopositivity of heat shock protein 60 as a biomarker of bronchial carcinogenesis. Lancet Oncol. 2005;6(10):816.PubMedCrossRef
206.
207.
Tang H, et al. Downregulation of HSP60 disrupts mitochondrial proteostasis to promote tumorigenesis and progression in clear cell renal cell carcinoma. Oncotarget. 2016;7(25):38822–34.PubMedPubMedCentralCrossRef
208.
Zhang J, et al. Hsp60 exerts a tumor suppressor function by inducing cell differentiation and inhibiting invasion in hepatocellular carcinoma. Oncotarget. 2016;7(42):68976–89.PubMedPubMedCentralCrossRef
209.
Faried A, et al. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer. 2004;40(18):2804–11.PubMedCrossRef
210.
Teng R, et al. HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells. Redox Biol. 2019;24: 101218.PubMedPubMedCentralCrossRef
211.
Fan W, et al. Elevated expression of HSP10 protein inhibits apoptosis and associates with poor prognosis of astrocytoma. PLoS ONE. 2017;12(10): e0185563.PubMedPubMedCentralCrossRef
212.
Feng J, et al. High expression of heat shock protein 10 (Hsp10) is associated with poor prognosis in oral squamous cell carcinoma. Int J Clin Exp Pathol. 2017;10(7):7784–91.PubMedPubMedCentral
213.
Feng J, et al. Increased expression of heat shock protein (HSP) 10 and HSP70 correlates with poor prognosis of nasopharyngeal carcinoma. Cancer Manag Res. 2019;11:8219–27.PubMedPubMedCentralCrossRef
214.
215.
216.
Kaul SC, et al. Three faces of mortalin: a housekeeper, guardian and killer. Exp Gerontol. 2007;42(4):263–74.PubMedCrossRef
217.
Wu PK, et al. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase. Mol Cell Biol. 2013;33(20):4051–67.PubMedPubMedCentralCrossRef
218.
Starenki D, et al. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. Oncogene. 2015;34(35):4624–34.PubMedCrossRef
219.
Starenki D, et al. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells. Int J Mol Sci. 2019;20(9):2069.PubMedCentralCrossRef
220.
Yi X, et al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics. 2008;7(2):315–25.PubMedCrossRef
221.
Wadhwa R, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer. 2006;118(12):2973–80.PubMedCrossRef
222.
Hu Y, et al. Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway. J Cell Mol Med. 2016;20(11):2111–21.PubMedPubMedCentralCrossRef
223.
Sun J, et al. Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer. Tumour Biol. 2017;39(3):1010428317695918.PubMedCrossRef
224.
Jin H, et al. The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast. J Exp Clin Cancer Res. 2016;35:42.PubMedPubMedCentralCrossRef
225.
Liu LX, et al. Mortalin stabilizes CD151-depedent tetraspanin-enriched microdomains and implicates in the progression of hepatocellular carcinoma. J Cancer. 2019;10(25):6199–206.PubMedPubMedCentralCrossRef
226.
Park SJ, et al. Down-regulation of mortalin exacerbates Abeta-mediated mitochondrial fragmentation and dysfunction. J Biol Chem. 2014;289(4):2195–204.PubMedCrossRef
227.
Kaul SC, et al. Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene. 1998;17(7):907–11.PubMedCrossRef
228.
229.
Na Y, et al. Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis. Cancer Res. 2016;76(9):2754–65.PubMedCrossRef
230.
Lu WJ, et al. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ. 2011;18(6):1046–56.PubMedPubMedCentralCrossRef
231.
Wadhwa R, et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem. 1998;273(45):29586–91.PubMedCrossRef
232.
Wadhwa R, et al. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res. 2002;274(2):246–53.PubMedCrossRef
233.
234.
Mylonis I, et al. Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK. J Biol Chem. 2008;283(41):27620–7.PubMedCrossRef
235.
Mylonis I, et al. Mortalin-mediated and ERK-controlled targeting of HIF-1alpha to mitochondria confers resistance to apoptosis under hypoxia. J Cell Sci. 2017;130(2):466–79.PubMed
236.
Wu PK, et al. Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability. Sci Signal. 2020;13(622):eaay1478.PubMedPubMedCentralCrossRef
237.
238.
Ben-Zvi A, et al. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci U S A. 2009;106(35):14914–9.PubMedPubMedCentralCrossRef
239.
240.
Tyedmers J, et al. Cellular strategies for controlling protein aggregation. Nat Rev Mol Cell Biol. 2010;11(11):777–88.PubMedCrossRef
241.
Cha SS, et al. Crystal structure of Lon protease: molecular architecture of gated entry to a sequestered degradation chamber. EMBO J. 2010;29(20):3520–30.PubMedPubMedCentralCrossRef
242.
Quiros PM, et al. ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. Cell Rep. 2014;8(2):542–56.PubMedCrossRef
243.
Ghosh JC, et al. Akt phosphorylation of mitochondrial Lonp1 protease enables oxidative metabolism and advanced tumor traits. Oncogene. 2019;38(43):6926–39.PubMedPubMedCentralCrossRef
244.
Liu C, et al. Inhibition of LONP1 suppresses pancreatic cancer progression Via c-Jun N-terminal kinase pathway-meditated epithelial-mesenchymal transition. Pancreas. 2019;48(5):629–35.PubMedCrossRef
245.
Gibellini L, et al. LonP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells. Front Oncol. 2018;8:254.PubMedPubMedCentralCrossRef
246.
247.
Cheng CW, et al. Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species. Cell Death Dis. 2013;4: e681.PubMedPubMedCentralCrossRef
248.
249.
Wang J, et al. The structure of ClpP at 2.3 A resolution suggests a model for ATP-dependent proteolysis. Cell. 1997;91(4):447–56.PubMedCrossRef
250.
Neher SB, et al. Distinct peptide signals in the UmuD and UmuD’ subunits of UmuD/D’ mediate tethering and substrate processing by the ClpXP protease. Proc Natl Acad Sci U S A. 2003;100(23):13219–24.PubMedPubMedCentralCrossRef
251.
Luo J, et al. ClpP regulates breast cancer cell proliferation, invasion and apoptosis by modulating the Src/PI3K/Akt signaling pathway. PeerJ. 2020;8: e8754.PubMedPubMedCentralCrossRef
252.
253.
Cole A, et al. Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2015;27(6):864–76.PubMedPubMedCentralCrossRef
254.
Zhang Y, Maurizi MR. (2016) Mitochondrial ClpP activity is required for cisplatin resistance in human cells. Biochim Biophys Acta. 1862;2:252–64.
255.
Kumar R, et al. A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60. J Clin Invest. 2022;132(13):e149906.PubMedPubMedCentralCrossRef
256.
Shkedi A, et al. Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer. Cell Chem Biol. 2022;29(3):490-501 e4.PubMedCrossRef
Metadata
Title
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer
Authors
Joseph R. Inigo
Dhyan Chandra
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01317-0

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Correspondence

Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients

Correspondence

Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients

Review

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

Review

3D chromatin architecture and transcription regulation in cancer

Review

Emerging role of exosomes in cancer progression and tumor microenvironment remodeling

Correspondence

Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits